The weekly litigation news digest is live. Subscribe now
Edaravone Suspension For Oral Administration - EP3875085
The patent EP3875085 was granted to Mitsubishi Tanabe Pharma on Jun 19, 2024. The application was filed on Nov 1, 2019 under application number EP19880770A. The patent is currently recorded with a legal status of "Granted And Under Opposition".
EP3875085
- Application Number
- EP19880770A
- Filing Date
- Nov 1, 2019
- Status
- Granted And Under Opposition
- May 17, 2024
- Publication Date
- Jun 19, 2024
- External Links
- Slate, Register, Google Patents
Patent Summary
Edaravone suspension for oral administration that achieves therapeutic efficacy comparable to intravenous injections while reducing the burden on patients and caregivers. The suspension contains edaravone particles dispersed in a water-based solution with added stabilizers and pH regulators. The formulation enables sustained release of edaravone through the gastrointestinal tract, with a dosing regimen of 90-120 mg per oral administration.
Patent Family
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Patent Citations (16) New
Patent citations refer to prior patents cited during different phases such as opposition or international search.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents